Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorder

Vaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib.

The company has also begun late-stage clinical testing of engasertib in patients with hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder.

HHT is caused by genetic mutations that produce abnormal blood vessels, leading to symptoms such as frequent nosebleeds, anemia and potential heart complications. Vaderis estimates the condition affects roughly one in 3,800 people in the United States.

CEO Azmi Nabulsi said the firm will explore strategic options after the trials, but the new funding positions Vaderis to fully execute its plans through 2029.